The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo; Gilead Sciences; Kyowa Hakko Kirin; MSD; Ono Pharmaceutical; Shionogi
 
Takaki Yoshikawa
Honoraria - Abbott Nutrition; Ajinomoto; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; Medtronic; Nihonkayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; MSD Oncology; Novartis
Research Funding - Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - AstraZeneca; Baxalta; Merck
Research Funding - Array BioPharma; AstraZeneca; Threshold Pharmaceuticals
 
Yoon-Koo Kang
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly/ImClone; Merck Serono; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - DAEHWA Pharmaceutical; LSK Biopharma
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck; MSD; Quintiles; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Lilly; Merck Serono
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Toshihiro Kudo
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Bayer Yakuhin; Chugai Pharma; Lilly; Ono Pharmaceutical; Yakult Honsha
 
Keisho Chin
Research Funding - AstraZeneca; Lilly; MDS; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical
 
Shigenori Kadowaki
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasuo Hamamoto
No Relationships to Disclose
 
Shuichi Hironaka
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Kazuhiro Yoshida
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Eisai; Johnson & Johnson; Lilly; Merck Serono; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Johnson & Johnson (Inst); KCI (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Eisai; Johnson & Johnson; Lilly; Merck Serono; MSD K.K; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
 
Chia-Jui Yen
No Relationships to Disclose
 
Yasushi Omuro
Research Funding - Lilly; MSD; Ono Pharmaceutical
 
Li-Yuan Bai
Consulting or Advisory Role - Lilly; MSD
 
Kaijiro Maeda
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Akichika Ozeki
Employment - Lilly Japan
Research Funding - Lilly Japan
Travel, Accommodations, Expenses - Lilly Japan
 
Reigetsu Yoshikawa
Employment - Lilly Japan
Stock and Other Ownership Interests - Lilly Japan
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medicon (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)